Holmium laser enucleation of the prostate versus transurethral resection in prostates ≥80 mL/g: a systematic review of urinary flow and hemorrhagic complications

Authors

  • Tom Oliveira da Cruz-Lima Cordeiro Centro Universitário UNINORTE Author
  • Ana Aisha Arruda Camarini da Silva Centro Universitário UNINORTE Author
  • João Lucas Dias Brito Centro Universitário UNINORTE Author
  • Stella Rocha de Morais Centro Universitário UNINORTE Author
  • Rafaela Maradey Hassem Centro Universitário UNINORTE Author
  • Maria Fernanda Santos de Almeida da Costa Centro Universitário UNINORTE Author

DOI:

https://doi.org/10.5281/zenodo.23806468

Keywords:

benign prostatic hyperplasia, HoLEP, transurethral resection of the prostate, urinary flow, bleeding.

Abstract

Introduction: Transurethral resection of the prostate (TURP) and holmium laser enucleation of the prostate (HoLEP) are effective procedures for benign prostatic obstruction, but comparisons in large glands are complicated by prior reviews combining TURP with other endoscopic modalities. Objective: To compare HoLEP with resection-based TURP in men with prostate volume ≥80 mL/g, focusing on maximum urinary flow rate (Qmax) and hemorrhagic complications. Methods: PRISMA 2020/PRISMA-S-oriented systematic review. On September 8, 2026, a structured search of an academic literature index was supplemented by tracking of primary studies, reviews, and bibliographic identifiers. Randomized trials and comparative studies were eligible when data were separable for prostates ≥80 mL/g and HoLEP was directly compared with TURP. Selection was performed by a single reviewer using a traceable decision log. Results: Eighteen unique reports were tracked; 15 underwent expanded assessment, 12 were excluded with reasons, and three studies were included: two randomized trials and one retrospective cohort. The randomized comparisons accounted for 234 participants in directly eligible arms. Both procedures improved urinary outcomes. One trial reported higher Qmax with HoLEP at 36 months, whereas another described comparable functional improvement. Hemorrhagic outcomes favored HoLEP. Quantitative pooling was not performed because at least two studies did not report dispersion measures or event counts in a compatible form. Conclusion: In prostates ≥80 mL/g, direct evidence suggests a hemostatic advantage for HoLEP and a possible late functional benefit, with low certainty of evidence.

References

ALTUNTAŞ, T.; SENER, T. E.; SAHAK, M. Y. et al. Comparison of TURP versus HoLEP: Is 80 g a reliable cut off? Journal of Clinical Urology, publicação online em 31 mar. 2025. DOI: 10.1177/20514158251315799.

CHE, X.; ZHOU, Z.; CHAI, Y.-C.; CUI, Y.; ZHANG, Y. The efficacy and safety of holmium laser enucleation of prostate compared with bipolar technologies in treating benign prostatic hyperplasia: a systematic review and meta-analysis of 10 randomized controlled trials. American Journal of Men’s Health, v. 16, n. 6, 2022. DOI: 10.1177/15579883221140211.

DARYANTO, B.; SURYANULLAH, W. S.; PUTRA, P. Y. P. Holmium laser enucleation of the prostate versus transurethral resection of the prostate in treatment of benign prostatic hyperplasia: a meta-analysis of 13 randomized control trials. Current Urology, 2024. DOI: 10.1097/CU9.0000000000000257.

ELSHAL, A. M.; SOLTAN, M.; EL-TABEY, N. A.; LAYMON, M.; NABEEH, A. Randomised trial of bipolar resection vs holmium laser enucleation vs Greenlight laser vapo-enucleation of the prostate for treatment of large benign prostate obstruction: 3-years outcomes. BJU International, v. 126, n. 6, p. 731-738, 2020. DOI: 10.1111/bju.15161.

HABIB, E.; ABDALLAH, M. F.; ELSHEEMY, M. S. et al. Holmium laser enucleation versus bipolar resection in the management of large-volume benign prostatic hyperplasia: a randomized controlled trial. International Journal of Urology, v. 29, n. 2, p. 128-135, 2022. DOI: 10.1111/iju.14737.

LI, S.; ZENG, X.-T.; RUAN, X.-L. et al. Holmium laser enucleation versus transurethral resection in patients with benign prostate hyperplasia: an updated systematic review with meta-analysis and trial sequential analysis. PLOS ONE, v. 9, n. 7, e101615, 2014. DOI: 10.1371/journal.pone.0101615.

PAGE, M. J.; MCKENZIE, J. E.; BOSSUYT, P. M. et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ, v. 372, n. 71, 2021. DOI: 10.1136/bmj.n71.

RETHLEFSEN, M. L.; KIRTLEY, S.; WAFFENSCHMIDT, S. et al. PRISMA-S: an extension to the PRISMA Statement for Reporting Literature Searches in Systematic Reviews. Systematic Reviews, v. 10, art. 39, 2021. DOI: 10.1186/s13643-020-01542-z.

STERNE, J. A. C.; HERNÁN, M. A.; REEVES, B. C. et al. ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions. BMJ, v. 355, i4919, 2016. DOI: 10.1136/bmj.i4919.

SUN, F.; YAO, H.; BAO, X. et al. The efficacy and safety of HoLEP for benign prostatic hyperplasia with large volume: a systematic review and meta-analysis. American Journal of Men’s Health, v. 16, n. 4, 2022. DOI: 10.1177/15579883221113203.

Published

2026-10-30

Issue

Section

Articles

How to Cite

CORDEIRO, Tom Oliveira da Cruz-Lima; SILVA, Ana Aisha Arruda Camarini da; BRITO, João Lucas Dias; MORAIS, Stella Rocha de; HASSEM, Rafaela Maradey; COSTA, Maria Fernanda Santos de Almeida da. Holmium laser enucleation of the prostate versus transurethral resection in prostates ≥80 mL/g: a systematic review of urinary flow and hemorrhagic complications. Journal of Social Issues and Health Sciences (JSIHS), [S. l.], v. 3, n. 4, 2026. DOI: 10.5281/zenodo.23806468. Disponível em: https://ojs.thesiseditora.com.br/index.php/jsihs/article/view/735.. Acesso em: 17 nov. 2026.